United States Patent 7,872,050: Claim Scope, Mechlorethamine Gel Protection, and Patent Landscape
U.S. Patent No. 7,872,050 protects methods of treating psoriasis, mycosis fungoides, and alopecia with topical compositions containing a pharmaceutically acceptable salt of bis(2-chloroethyl)methylamine, commonly known as mechlorethamine or nitrogen mustard. The core commercial embodiment is mechlorethamine hydrochloride in a nonaqueous gel containing ethoxy diglycol and an organic acid, particularly lactic acid.
The patent is a method-of-treatment patent rather than a broad composition patent. Its practical value depends on whether a competing product is used for a claimed disease, contains the claimed active-ingredient concentration, and uses the specified vehicle and acid limitations. The patent does not cover every topical mechlorethamine product.
The principal commercial product associated with this technology is VALCHLOR, a 0.016% mechlorethamine hydrochloride gel approved by the U.S. Food and Drug Administration for topical treatment of Stage IA and IB mycosis fungoides in patients who received prior skin-directed therapy.[1]
What does U.S. Patent 7,872,050 cover?
The independent claim covers a treatment method with five required elements:
- A person has psoriasis, mycosis fungoides, or alopecia.
- A composition is topically applied to affected skin.
- The active pharmaceutical ingredient consists essentially of a pharmaceutically acceptable salt of bis(2-chloroethyl)methylamine.
- The vehicle or carrier is a compound within the formula HOCH2CH2OCH2CH2OR79, where R79 is a linear C1-C6 alkyl group.
- The composition contains an organic acid at approximately 1% to 15% by weight.
The claim is cumulative. A product that contains mechlorethamine but lacks the claimed vehicle or organic-acid range does not satisfy claim 1 literally.
What is the active ingredient covered by the patent?
Bis(2-chloroethyl)methylamine is the chemical entity commonly called mechlorethamine, nitrogen mustard, or mustine. The claim requires a pharmaceutically acceptable salt rather than necessarily the uncharged free base.
The commercially relevant salt is mechlorethamine hydrochloride. The patent language "consists essentially of" permits the claimed active pharmaceutical ingredient to contain the specified salt while allowing components that do not materially alter the basic therapeutic characteristics of the composition.
What vehicle does the patent require?
The claimed vehicle has the structure:
HOCH2CH2OCH2CH2OR79
where R79 is a linear alkyl group containing one to six carbon atoms.
The most commercially relevant species is R79 equal to ethyl, producing diethylene glycol monoethyl ether, commonly called ethoxy diglycol or Transcutol.
| R79 group |
Resulting vehicle |
| Methyl |
Diethylene glycol monomethyl ether |
| Ethyl |
Diethylene glycol monoethyl ether, ethoxy diglycol |
| Propyl |
Diethylene glycol monopropyl ether |
| Butyl |
Diethylene glycol monobutyl ether |
| Pentyl |
Diethylene glycol monopentyl ether |
| Hexyl |
Diethylene glycol monohexyl ether |
Claims 7, 12, 13, and 14 narrow the vehicle requirement to ethoxy diglycol. Claims 13 and 14 also require lactic acid.
How do the 14 claims differ?
Claims 1 through 14 form a layered claim set. The principal limitations are summarized below.
| Claim |
Scope |
| 1 |
Topical treatment of psoriasis, mycosis fungoides, or alopecia using a mechlorethamine salt, claimed glycol-ether vehicle, and 1%-15% organic acid |
| 2 |
Active ingredient concentration of 0.0001%-2.0% |
| 3 |
Active ingredient concentration of 0.01%-0.04% |
| 4 |
Active ingredient concentration of 0.015%-0.030% |
| 5 |
Organic acid selected from a long Markush group |
| 6 |
Organic acid is lactic acid |
| 7 |
Vehicle is ethoxy diglycol |
| 8 |
Disease is mycosis fungoides |
| 9 |
Disease is psoriasis |
| 10 |
Disease is alopecia |
| 11 |
Vehicle is nonaqueous |
| 12 |
Nonaqueous vehicle is ethoxy diglycol |
| 13 |
Ethoxy diglycol vehicle plus lactic acid |
| 14 |
Nonaqueous ethoxy diglycol vehicle plus lactic acid |
Claim 1 is the broadest asserted method claim in the provided set. Claims 13 and 14 are narrower but commercially important because they describe the apparent VALCHLOR-type formulation more closely.
What concentration range is commercially important?
VALCHLOR contains 0.016% mechlorethamine hydrochloride. That concentration falls within all three concentration ranges in claims 2, 3, and 4:
| Claim range |
Does 0.016% fall within the range? |
| 0.0001%-2.0% |
Yes |
| 0.01%-0.04% |
Yes |
| 0.015%-0.030% |
Yes |
A competing product at 0.016% therefore meets the concentration limitations of claims 2 through 4, assuming the product also satisfies the vehicle, organic-acid, and disease-use limitations.
What formulations are protected by U.S. Patent 7,872,050?
The strongest formulation-specific coverage is directed to a nonaqueous mechlorethamine gel containing ethoxy diglycol and lactic acid.
The claim set does not require the formulation to be a gel. A cream, ointment, solution, or other topical dosage form could fall within the claims if it contains the required active ingredient, vehicle, organic acid, and concentration ranges. The claims therefore focus on composition chemistry and therapeutic use rather than a particular rheological form.
Does VALCHLOR fit the claimed formulation?
VALCHLOR is a 0.016% mechlorethamine hydrochloride topical gel. Its FDA labeling identifies inactive ingredients that include ethoxy diglycol and lactic acid.[1] The product therefore aligns closely with the limitations of claims 3, 4, 6, 7, 13, and 14 when used for the FDA-approved mycosis fungoides indication.
The claim analysis is:
| VALCHLOR characteristic |
Relevant patent limitation |
| Mechlorethamine hydrochloride |
Pharmaceutically acceptable salt of bis(2-chloroethyl)methylamine |
| 0.016% strength |
Claims 2, 3, and 4 |
| Ethoxy diglycol |
Claims 7, 12, 13, and 14 |
| Lactic acid |
Claims 6, 13, and 14 |
| Nonaqueous topical gel |
Claims 11, 12, and 14 |
| Mycosis fungoides treatment |
Claims 1 and 8 |
The product’s FDA-approved use is narrower than the patent’s disease list. The patent claims psoriasis and alopecia as well as mycosis fungoides, while the VALCHOR label is directed to Stage IA and IB mycosis fungoides.
What are the principal infringement issues?
Does a product infringe if it contains mechlorethamine but uses a different vehicle?
Not necessarily. Claim 1 requires the claimed glycol-ether vehicle. A product using only water, petrolatum, mineral oil, propylene glycol, or another carrier could avoid literal infringement if it does not contain a compound within the claimed formula.
The doctrine of equivalents could become relevant, but the result would depend on prosecution history, claim construction, and the technical differences between the accused vehicle and ethoxy diglycol. The supplied claim text alone does not resolve that issue.
Does a product infringe if it omits organic acid?
Claim 1 requires an organic acid at approximately 1%-15% by weight. A formulation without an organic acid would have a substantial noninfringement position under the literal claim language.
A product containing an acid below 1% would also fall outside the express range, subject to potential equivalents analysis.
Does the disease indication matter?
Yes. The claims are method claims tied to treatment of psoriasis, mycosis fungoides, or alopecia. A manufacturer’s label, promotional activity, clinical trial design, or other evidence of intended use may affect infringement analysis.
A product sold for an unclaimed dermatologic indication would not automatically infringe. Conversely, an off-label use by physicians could create a different factual analysis from the manufacturer’s activities.
Does the phrase "consists essentially of" exclude combination therapy?
The active pharmaceutical ingredient must consist essentially of the specified pharmaceutically acceptable salt. The phrase is narrower than "comprising" and may exclude additional active ingredients that materially alter the claimed composition or therapeutic characteristics. It does not necessarily exclude inactive excipients or a second active ingredient in every circumstance, but a combination product would require detailed claim-construction analysis.
When does U.S. Patent 7,872,050 lose exclusivity?
The patent issued on January 18, 2011.[2] Its enforceable term is determined from the relevant nonprovisional filing date, adjusted by any patent-term adjustment, terminal disclaimer, or other USPTO-recorded term modification. The patent’s baseline 20-year term falls in the 2025-2026 period based on the family filing record.
The issue date does not control expiration. A commercial freedom-to-operate analysis should use the USPTO Patent Center term calculation and review any patent-term adjustment certificate. Patent expiration also does not eliminate separate Orange Book patents, regulatory exclusivity, or later patents covering other formulations or uses.
| Exclusivity element |
Relevance |
| U.S. Patent 7,872,050 |
Core topical mechlorethamine method claims |
| FDA approval of VALCHOR |
Approved in 2013 |
| New chemical entity exclusivity |
Five-year period generally associated with the original NDA, subject to statutory exceptions |
| Orange Book patents |
Must be assessed separately from this patent’s claim text |
| Pediatric exclusivity |
Could extend listed patent and exclusivity periods if awarded |
| Later formulation patents |
May extend commercial protection beyond the term of this patent |
What is the FDA and Orange Book status of mechlorethamine gel?
FDA approved VALCHOR, mechlorethamine gel 0.016%, in August 2013 under NDA 202317 for topical treatment of Stage IA and IB mycosis fungoides.[1] The product is a drug-device-like topical presentation packaged for refrigerated storage and controlled handling because mechlorethamine is a cytotoxic alkylating agent.
The Orange Book must be reviewed by product and NDA. A patent listed for VALCHOR may cover the formulation, method of use, or both. Patent 7,872,050 should not be assumed to be the only patent relevant to an ANDA or 505(b)(2) application.
FDA Orange Book listing categories generally distinguish:
- Drug substance patents.
- Drug product or formulation patents.
- Method-of-use patents.
- Patents with use codes that limit the listed indication.
A Paragraph IV certification against a listed patent would require the generic applicant to assert that the patent is invalid, unenforceable, or will not be infringed. The certification would not automatically invalidate the patent or authorize immediate launch.
Which companies are challenging VALCHLOR patent rights?
Publicly available FDA and patent records should be used to identify current ANDA applicants, Paragraph IV notices, and litigation. The supplied claim text does not establish a particular challenger, and a patent-number-only review does not reliably identify every Orange Book dispute.
The relevant competitive pathways are:
| Pathway |
Potential entrant |
Principal patent issue |
| ANDA |
Generic mechlorethamine gel |
Bioequivalence and listed patents |
| 505(b)(2) NDA |
Alternative mechlorethamine topical product |
Clinical bridging and formulation differences |
| Compounded product |
Pharmacy-prepared mechlorethamine |
Regulatory status, quality, and claim scope |
| Off-label product |
Existing mechlorethamine formulation |
Intended-use and vehicle limitations |
A generic that reproduces the 0.016% ethoxy-diglycol/lactic-acid formulation would face a stronger infringement case under claims 3, 4, 6, 7, 13, and 14 than a generic using a materially different vehicle or acid system.
What patent litigation and settlement risks apply?
The principal litigation risks are:
- Claim construction over "consists essentially of."
- Whether a formulation contains the claimed glycol ether in a legally sufficient amount.
- Whether the organic acid concentration is within the 1%-15% range.
- Whether a generic label induces treatment of mycosis fungoides.
- Whether later Orange Book patents remain enforceable after this patent expires.
- Whether a Paragraph IV settlement delays generic launch.
A settlement could provide a licensed entry date before patent expiration, but the terms would depend on the parties and applicable antitrust review. No settlement terms can be inferred from the claim text.
How strong is the patent estate?
U.S. Patent 7,872,050 has meaningful but limited strength.
Strengths
- It captures the commercial 0.016% concentration.
- It covers the commercially relevant ethoxy diglycol vehicle.
- It specifically covers lactic acid.
- It includes mycosis fungoides, the approved VALCHOR indication.
- It provides dependent claims that create multiple infringement theories.
Weaknesses
- The patent does not broadly cover every mechlorethamine topical composition.
- Vehicle and acid limitations create design-around opportunities.
- The disease limitations restrict method-of-use enforcement.
- The patent term is near or within its final statutory period based on the family filing record.
- A competitor could pursue a different vehicle, acid system, dosage form, concentration, or indication.
The estate is strongest against a direct copy of the VALCHOR formulation and its approved mycosis fungoides use. It is weaker against nonaqueous formulations that replace ethoxy diglycol or omit the claimed organic-acid range.
How does the patent compare with biosimilar and generic risk?
Biosimilar risk is not applicable in the conventional statutory sense because mechlorethamine gel is a small-molecule drug, not a biologic. The relevant threat is generic or 505(b)(2) competition.
| Risk category |
Assessment |
| Biosimilar substitution |
Not applicable |
| Small-molecule ANDA |
Principal regulatory pathway |
| 505(b)(2) product |
Material risk if formulation differs |
| Compounding |
Commercial and regulatory pressure, but not automatically substitutive |
| Formulation design-around |
Feasible in principle |
| Direct VALCHOR copy |
Highest patent exposure before enforceable expiry |
What generic launch scenarios exist?
Scenario 1: Direct formulation copy
A generic matching 0.016% mechlorethamine hydrochloride, ethoxy diglycol, lactic acid, and a mycosis fungoides label would face the highest exposure under the asserted claims and any related Orange Book patents.
Scenario 2: Vehicle substitution
Replacing ethoxy diglycol with a nonclaimed solvent could avoid literal infringement of claims 7, 12, 13, and 14. The generic would still need to assess claim 1 and the doctrine of equivalents.
Scenario 3: Acid substitution
Using a different organic acid listed in claim 5 would not necessarily avoid the patent. Claim 5 expressly includes numerous acids, and claim 1 covers an organic acid generally within the specified range.
Scenario 4: Acid omission
Removing the organic acid could avoid the principal independent claim, although product performance, stability, skin penetration, and FDA comparability would need to be addressed.
Scenario 5: Indication carve-out
A generic may attempt to omit mycosis fungoides or other protected uses from its labeling. A carve-out would not eliminate all risks if marketing or product design encourages the protected use.
What geographic coverage does the patent provide?
U.S. Patent 7,872,050 provides protection only in the United States. Foreign counterparts must be analyzed separately by jurisdiction. The commercial assessment should distinguish:
- United States patent and Orange Book rights.
- European Patent Convention designations.
- United Kingdom national rights.
- Canadian rights.
- Japanese and other Asian family members.
- Regulatory exclusivity in each market.
Patent expiration, claim language, prosecution history, supplementary protection certificates, and product-label rules differ by jurisdiction. U.S. expiration does not establish foreign freedom to operate.
Key Takeaways
- U.S. Patent 7,872,050 is a method-of-treatment patent for topical mechlorethamine formulations.
- Its core limitations are mechlorethamine salt, a specified glycol-ether vehicle, 1%-15% organic acid, and treatment of psoriasis, mycosis fungoides, or alopecia.
- Ethoxy diglycol and lactic acid are the most commercially important limitations.
- The 0.016% VALCHLOR strength falls within the patent’s three concentration ranges.
- Claims 13 and 14 closely track a nonaqueous ethoxy-diglycol/lactic-acid formulation.
- The patent is strongest against a direct copy of VALCHLOR used for mycosis fungoides.
- It does not broadly block every topical mechlorethamine formulation.
- Generic risk is more relevant than biosimilar risk.
- Vehicle substitution, acid omission, concentration changes, and indication carve-outs are the principal design-around strategies.
- The patent’s baseline term falls in the 2025-2026 period, subject to the USPTO-recorded term calculation and any related patents.
- Orange Book-listed patents and later formulation patents must be reviewed independently before assessing launch timing.
Frequently Asked Questions
Is U.S. Patent 7,872,050 a composition patent?
No. The provided claims are method claims requiring topical administration to treat specified skin disorders. The patent does not independently claim every composition containing mechlorethamine.
Does the patent cover mechlorethamine hydrochloride at 0.016%?
Yes, when the product also contains the claimed vehicle and organic acid and is used for one of the claimed disorders. The 0.016% concentration falls within claims 2, 3, and 4.
Is ethoxy diglycol the same as diethylene glycol monoethyl ether?
Yes. Ethoxy diglycol is the common name for diethylene glycol monoethyl ether, the ethyl-substituted compound within the claimed vehicle formula.
Can a generic avoid the patent by changing the acid?
Not necessarily. Claim 5 lists multiple organic acids, and claim 1 covers an organic acid generally within the 1%-15% range. Changing from lactic acid to another listed acid may remain within the patent.
Does the patent block use of mechlorethamine for all cancers?
No. The provided claims are limited to psoriasis, mycosis fungoides, and alopecia. They do not expressly cover every cancer indication or every topical use of mechlorethamine.
References
-
U.S. Food and Drug Administration. (2013). VALCHLOR (mechlorethamine) gel, 0.016% prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
United States Patent and Trademark Office. (2011). U.S. Patent No. 7,872,050, topical formulations and methods involving mechlorethamine. Patent Center. https://patentcenter.uspto.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation resources. https://www.uspto.gov/patents/laws/patent-term-adjustment-patent-term-extension-rules
